Tiange Yu

Tiange Yu

Auto-generated profile, based on publicly available information

Tiange Yu

Genesis Research Group

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
21 December 2020 in Journal of Urology
Verified
Journal Article
Open access
IJIrum Javed
Irum Javed
TYTiange Yu
Tiange Yu
JLJieni Li
Jieni Li
RPRatna Pakpahan
Ratna Pakpahan
MMMelissa Milbrandt
Melissa Milbrandt
SSSiobhan Sutcliffe
Siobhan Sutcliffe
Purpose:To determine whether pollen triggers urologic chronic pelvic pain syndrome (UCPPS) flares.Materials and Methods:We assessed flare status every two weeks for one year as part of the Multidis...

31 July 2026 in medRxiv
Verified
Preprint
Open access
PDF file
LZLaura D. Zambrano
Laura D. Zambrano
TYTiange Yu
Tiange Yu
JMJazmine Mateus
Jazmine Mateus
XZXin Zhao
Xin Zhao
KAKathleen M. Andersen
Kathleen M. Andersen
HVHannah R Volkman
Hannah R Volkman
Evidence on vaccine effectiveness (VE) of 2025-26 COVID-19 vaccines is limited. We estimated VE of BNT162b2 LP.8.1-adapted vaccine among non-immunocompromised adults ≥65 years through December 2025 using linked claims and immunization registry data from two U.S. states. VE against COVID-19-related ED/UC encounters was 48% (95% CI:19, 66).

29 May 2025 in medRxiv
Verified
Preprint
Open access
PDF file
KAKathleen M. Andersen
Kathleen M. Andersen
TATara Ahi
Tara Ahi
JMJazmine S. Mateus
Jazmine S. Mateus
TYTiange Yu
Tiange Yu
AZAnan Zhou
Anan Zhou
LPLaura A. Puzniak
Laura A. Puzniak
Background: Data are limited on 2024-2025 BNT162b2 COVID-19 vaccine effectiveness (VE). Methods: Retrospective cohort study among non-immunocompromised adults from August 22, 2024 (“index”) to December 31, 2024, among residents of California or Louisiana continuously enrolled in health insurance plans reporting to HealthVerity for ≥1 year prior to index. Receipt of 2024-2025 BNT162b2 COVID-19 vaccine was defined using state vaccine registries with health insurance claims, using a time-varying exposure definition. VE against COVID-19-associated hospital admissions was estimated as (1-hazard ratio), using adjusted Cox proportional hazards models with 95% confidence intervals (CI). Results: Overall, 6,900,361 individuals met selection criteria for the study. By the end of follow-up (median 4.4 months), 325,362 (4.7%) had received a BNT162b2 2024-2025 COVID-19 vaccine dose. VE against COVID-19-associated hospital admission was 41% (95% CI 2-64). Discussion: The 2024-2025 formulation of BNT162b2 COVID-19 vaccine provided significant protection, particularly for older adults, in mid-season estimates. This study is registered on clinicaltrials.gov as NCT06923137 .

13 November 2025 in American Journal of Epidemiology
Verified
Journal Article
Open access
KAKathleen M Andersen
Kathleen M Andersen
LMLeah J McGrath
Leah J McGrath
KAKristen E Allen
Kristen E Allen
FKFarid L Khan
Farid L Khan
TYTiange Yu
Tiange Yu
LPLaura Puzniak
Laura Puzniak
Purpose: To describe a novel data ecosystem and quantify improvements in documented COVID-19 vaccine uptake using closed claims data and state vaccine registries. Methods: De-identified data from administrative claims were linked via tokenization to state vaccine registry data from two states with mandatory vaccine reporting. COVID-19 vaccine uptake in claims alone versus supplemented with registry data was measured separately for original wildtype, BA.4/5-adapted bivalent, and XBB.1.5-adapted formulations. Results: There were over 9 million individuals included in each formulation distribution study period. Using claims data alone versus with additional state registry data, 20% versus 57% of individuals had documented receipt of a primary wildtype series (≥2 doses of two-dose or ≥ 1 of single-dose series), 7% versus 10% BA.4/5-adapted bivalent, and 6% versus 8% XBB.1.5-adapted COVID-19 vaccine. Most claims-based vaccination events were captured with drug, rather than procedure, codes. Individuals with Medicaid-based insurance were less likely to be captured as vaccinated in claims data. Conclusions: The addition of state vaccine registries increased COVID-19 vaccine capture by 182% for primary wildtype series, 41% BA.4/5-adapted bivalent, and 38% XBB.1.5-adapted formulations. Tokenization of claims data to vaccine registries presents an opportunity for more accurate estimates of vaccine uptake and effectiveness than claims data alone.

11 August 2026 in Journal of Medical Economics
Verified
Journal Article
Open access
JMJaromir Mikl
Jaromir Mikl
TYTiange Yu
Tiange Yu
XZXin Zhao
Xin Zhao
CACatherine Allende
Catherine Allende
ADAmie Devlin
Amie Devlin
RDRoger Dmochowski
Roger Dmochowski
Interstitial cystitis/bladder pain syndrome (IC/BPS) is a chronic, heterogeneous condition within the broader definition of urologic chronic pelvic pain syndrome [1,2]. It is diagnosed by exclusion...